Mackenzie Financial Corp Has $8.32 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Mackenzie Financial Corp lessened its stake in Kenvue Inc. (NYSE:KVUE) by 88.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 386,450 shares of the company’s stock after selling 3,099,080 shares during the quarter. Mackenzie Financial Corp’s holdings in Kenvue were worth $8,320,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Clearstead Advisors LLC acquired a new stake in Kenvue in the 3rd quarter valued at about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $27,000. AdvisorNet Financial Inc acquired a new stake in shares of Kenvue during the 3rd quarter worth approximately $28,000. Global Retirement Partners LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth approximately $28,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth approximately $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $19.58 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80. The firm’s 50 day moving average price is $19.84 and its two-hundred day moving average price is $20.16.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. The company’s revenue was down 2.7% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.09%. The ex-dividend date of this dividend was Tuesday, February 13th.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on KVUE shares. William Blair started coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. Royal Bank of Canada lowered their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Sanford C. Bernstein started coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target for the company. The Goldman Sachs Group started coverage on shares of Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.